Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
8.88
+0.16 (1.83%)
Nov 5, 2024, 11:19 AM EST - Market open
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ARQT stock have an average target of 14.4, with a low estimate of 10 and a high estimate of 18. The average target predicts an increase of 62.16% from the current stock price of 8.88.
Analyst Consensus: Buy
* Price targets were last updated on Aug 28, 2024.
Analyst Ratings
The average analyst rating for ARQT stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +68.92% | Aug 28, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +102.70% | Aug 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +102.70% | Jul 30, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +102.70% | Jul 10, 2024 |
| Needham | Needham | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | +102.70% | May 15, 2024 |
Financial Forecast
Revenue This Year
169.59M
from 59.61M
Increased by 184.52%
Revenue Next Year
253.47M
from 169.59M
Increased by 49.46%
EPS This Year
-1.58
from -3.78
EPS Next Year
-1.17
from -1.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 181.7M | 313.5M | 462.0M | ||
| Avg | 169.6M | 253.5M | 402.5M | ||
| Low | 158.3M | 201.5M | 267.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 204.8% | 84.9% | 82.3% | ||
| Avg | 184.5% | 49.5% | 58.8% | ||
| Low | 165.5% | 18.8% | 5.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.49 | -0.82 | 0.30 | ||
| Avg | -1.58 | -1.17 | -0.16 | ||
| Low | -1.75 | -1.35 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.